UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1282-7
Program Prior Authorization/Notification
Medication Samsca® (tolvaptan)
P&T Approval Date 6/2019, 6/2020, 6/2021, 6/2022, 6/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Samsca is a selective vasopressin V -receptor antagonist indicated for the treatment of
2
clinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125
mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with
fluid restriction), including patients with heart failure and Syndrome of Inappropriate
Antidiuretic Hormone (SIADH).1
Limitations of Use:
• Patients requiring intervention to raise serum sodium urgently to prevent or to treat
serious neurological symptoms should not be treated with Samsca.
• It has not been established that Samsca provides a symptomatic benefit to patients.
2. Coverage Criteriaa:
A. Hypervolemic or Euvolemic Hyponatremia
1. Samsca will be approved based on all of the following:
a. One of the following:
(1) Diagnosis of clinically significant euvolemic hyponatremia
-OR-
(2) Diagnosis of clinically significant hypervolemic hyponatremia
-AND-
b. Patient has not responded to fluid restriction
-AND-
c. Treatment has been initiated or re-initiated in a hospital setting prior to discharge
Authorization will be issued for 30 days.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Samsca [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; April
2021.
Program Prior Authorization/Notification – Samsca (tolvaptan)
Change Control
6/2019 New program.
6/2020 Annual review. No changes to criteria.
6/2021 Annual review. No changes to criteria. Updated background and
references.
6/2022 Annual review. No changes to criteria. Updated background and
references.
6/2023 Annual review with no changes to criteria. Added state mandate
footnote.
6/2024 Annual review with no changes to criteria. Updated formatting of
background.
6/2025 Annual review with no changes to criteria.
© 2025 UnitedHealthcare Services Inc.
2